Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 8/20 | 0.49 |
| ▸ | TYMP | P19971 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.36 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.35 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.35 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.35 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579965 | 1.00 | DUT (0.49) | DUTTYMPHSP90AA1RNASE1P2RY2 | |
| SCHEMBL29722701 | 0.87 | DUT (0.54) | DUTTYMPHSP90AA1RNASE1P2RY2 | |
| SCHEMBL3574271 | 0.85 | DUT (0.49) | DUTTYMPHSP90AA1RNASE1MEN1 | |
| SCHEMBL9221159 | 0.84 | DUT (0.50) | DUTTYMPHSP90AA1RNASE1P2RY2 | |
| SCHEMBL3925356 | 0.84 | DUT (0.50) | DUTTYMPHSP90AA1RNASE1P2RY2 | |
| SCHEMBL9552004 | 0.84 | DUT (0.50) | DUTTYMPHSP90AA1RNASE1P2RY2 | |
| SCHEMBL3576747 | 0.82 | DUT (0.68) | DUTTYMPP2RY2P2RY4P2RY6 | |
| SCHEMBL10446525 | 0.82 | DUT (0.68) | DUTTYMPP2RY2P2RY4P2RY6 | |
| SCHEMBL3492644 | 0.82 | DUT (0.68) | DUTTYMPP2RY2P2RY4P2RY6 | |
| SCHEMBL3583645 | 0.82 | DUT (0.55) | DUTTYMPHSP90AA1P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075924-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2010-03-25 | — | — | US | disclosed |
| US-7601702-B2 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2009-10-13 | — | — | US | disclosed |
| US-20080300216-A1 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300216-A1 | Dutpase Inhibitors | DUT, DHODH, POLR2H | DUT 1/4885TYMP 32/4885HSP90AA1 4778/4885 |
| US-20100075924-A1 | DUTPASE INHIBITORS | DUT, DHODH, CCNO | DUT 1/4885TYMP 39/4885HSP90AA1 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.